Cargando…

AMP-activated protein kinase modulates tau phosphorylation and tau pathology in vivo

Neurofibrillary tangles (NFTs) are the pathological hallmark of neurodegenerative diseases commonly known as tauopathies. NFTs result from the intracellular aggregation of abnormally and hyperphosphorylated tau proteins. Tau functions, which include the regulation of microtubules dynamics, are depen...

Descripción completa

Detalles Bibliográficos
Autores principales: Domise, Manon, Didier, Sébastien, Marinangeli, Claudia, Zhao, Haitian, Chandakkar, Pallavi, Buée, Luc, Viollet, Benoit, Davies, Peter, Marambaud, Philippe, Vingtdeux, Valérie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4882625/
https://www.ncbi.nlm.nih.gov/pubmed/27230293
http://dx.doi.org/10.1038/srep26758
_version_ 1782434146937733120
author Domise, Manon
Didier, Sébastien
Marinangeli, Claudia
Zhao, Haitian
Chandakkar, Pallavi
Buée, Luc
Viollet, Benoit
Davies, Peter
Marambaud, Philippe
Vingtdeux, Valérie
author_facet Domise, Manon
Didier, Sébastien
Marinangeli, Claudia
Zhao, Haitian
Chandakkar, Pallavi
Buée, Luc
Viollet, Benoit
Davies, Peter
Marambaud, Philippe
Vingtdeux, Valérie
author_sort Domise, Manon
collection PubMed
description Neurofibrillary tangles (NFTs) are the pathological hallmark of neurodegenerative diseases commonly known as tauopathies. NFTs result from the intracellular aggregation of abnormally and hyperphosphorylated tau proteins. Tau functions, which include the regulation of microtubules dynamics, are dependent on its phosphorylation status. As a consequence, any changes in tau phosphorylation can have major impacts on synaptic plasticity and memory. Recently, it has been demonstrated that AMP-activated protein kinase (AMPK) was deregulated in the brain of Alzheimer’s disease (AD) patients where it co-localized with phosphorylated tau in pre-tangle and tangle-bearing neurons. Besides, it was found that AMPK was a tau kinase in vitro. Here, we find that endogenous AMPK activation in mouse primary neurons induced an increase of tau phosphorylation at multiple sites, whereas AMPK inhibition led to a rapid decrease of tau phosphorylation. We further show that AMPK mice deficient for one of the catalytic alpha subunits displayed reduced endogenous tau phosphorylation. Finally, we found that AMPK deficiency reduced tau pathology in the PS19 mouse model of tauopathy. These results show that AMPK regulates tau phosphorylation in mouse primary neurons as well as in vivo, and thus suggest that AMPK could be a key player in the development of AD pathology.
format Online
Article
Text
id pubmed-4882625
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-48826252016-06-07 AMP-activated protein kinase modulates tau phosphorylation and tau pathology in vivo Domise, Manon Didier, Sébastien Marinangeli, Claudia Zhao, Haitian Chandakkar, Pallavi Buée, Luc Viollet, Benoit Davies, Peter Marambaud, Philippe Vingtdeux, Valérie Sci Rep Article Neurofibrillary tangles (NFTs) are the pathological hallmark of neurodegenerative diseases commonly known as tauopathies. NFTs result from the intracellular aggregation of abnormally and hyperphosphorylated tau proteins. Tau functions, which include the regulation of microtubules dynamics, are dependent on its phosphorylation status. As a consequence, any changes in tau phosphorylation can have major impacts on synaptic plasticity and memory. Recently, it has been demonstrated that AMP-activated protein kinase (AMPK) was deregulated in the brain of Alzheimer’s disease (AD) patients where it co-localized with phosphorylated tau in pre-tangle and tangle-bearing neurons. Besides, it was found that AMPK was a tau kinase in vitro. Here, we find that endogenous AMPK activation in mouse primary neurons induced an increase of tau phosphorylation at multiple sites, whereas AMPK inhibition led to a rapid decrease of tau phosphorylation. We further show that AMPK mice deficient for one of the catalytic alpha subunits displayed reduced endogenous tau phosphorylation. Finally, we found that AMPK deficiency reduced tau pathology in the PS19 mouse model of tauopathy. These results show that AMPK regulates tau phosphorylation in mouse primary neurons as well as in vivo, and thus suggest that AMPK could be a key player in the development of AD pathology. Nature Publishing Group 2016-05-27 /pmc/articles/PMC4882625/ /pubmed/27230293 http://dx.doi.org/10.1038/srep26758 Text en Copyright © 2016, Macmillan Publishers Limited http://creativecommons.org/licenses/by/4.0/ This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/
spellingShingle Article
Domise, Manon
Didier, Sébastien
Marinangeli, Claudia
Zhao, Haitian
Chandakkar, Pallavi
Buée, Luc
Viollet, Benoit
Davies, Peter
Marambaud, Philippe
Vingtdeux, Valérie
AMP-activated protein kinase modulates tau phosphorylation and tau pathology in vivo
title AMP-activated protein kinase modulates tau phosphorylation and tau pathology in vivo
title_full AMP-activated protein kinase modulates tau phosphorylation and tau pathology in vivo
title_fullStr AMP-activated protein kinase modulates tau phosphorylation and tau pathology in vivo
title_full_unstemmed AMP-activated protein kinase modulates tau phosphorylation and tau pathology in vivo
title_short AMP-activated protein kinase modulates tau phosphorylation and tau pathology in vivo
title_sort amp-activated protein kinase modulates tau phosphorylation and tau pathology in vivo
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4882625/
https://www.ncbi.nlm.nih.gov/pubmed/27230293
http://dx.doi.org/10.1038/srep26758
work_keys_str_mv AT domisemanon ampactivatedproteinkinasemodulatestauphosphorylationandtaupathologyinvivo
AT didiersebastien ampactivatedproteinkinasemodulatestauphosphorylationandtaupathologyinvivo
AT marinangeliclaudia ampactivatedproteinkinasemodulatestauphosphorylationandtaupathologyinvivo
AT zhaohaitian ampactivatedproteinkinasemodulatestauphosphorylationandtaupathologyinvivo
AT chandakkarpallavi ampactivatedproteinkinasemodulatestauphosphorylationandtaupathologyinvivo
AT bueeluc ampactivatedproteinkinasemodulatestauphosphorylationandtaupathologyinvivo
AT violletbenoit ampactivatedproteinkinasemodulatestauphosphorylationandtaupathologyinvivo
AT daviespeter ampactivatedproteinkinasemodulatestauphosphorylationandtaupathologyinvivo
AT marambaudphilippe ampactivatedproteinkinasemodulatestauphosphorylationandtaupathologyinvivo
AT vingtdeuxvalerie ampactivatedproteinkinasemodulatestauphosphorylationandtaupathologyinvivo